Pulmonary Arterial Hypertension (PAH) Market in China 2023
Pulmonary Arterial Hypertension (PAH) is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. It occurs when the pulmonary arteries, which carry blood from the heart to the lungs to pick up oxygen, become narrowed and stiff, resulting in increased resistance to blood flow and higher blood pressure in the arteries. PAH can cause symptoms such as shortness of breath, fatigue, chest pain, dizziness, and fainting. It can also lead to complications such as heart failure, blood clots, and infections. The pulmonary arterial hypertension market in China is projected to rise by USD 913.9 million by 2029, according to the latest market study results. It is anticipated to expand at a CAGR of 39.27 percent during the forecast period.
This industry report offers market estimates of the China market, followed by a detailed analysis of the region. The China market data on pulmonary arterial hypertension can be segmented by region: Central South China, East China, North China, Northeast China, Northwest China, Southwest China.
The report also includes the profiles of leading companies such as Actelion Pharmaceuticals Ltd., Bayer AG, Beijing Tide Pharmaceutical Co. Ltd., GlaxoSmithKline plc, United Therapeutics Corporation.
The data-centric report focuses on market trends, status and outlook for segments. With comprehensive market assessment across the major geographies, the report is a valuable asset for the existing players, new entrants and the future investors.
Why buy this report?
Get a detailed picture of the China Pulmonary Arterial Hypertension Market
Identify segments/areas to invest in over the forecast period in the China Pulmonary Arterial Hypertension Market
Understand the competitive environment, the market’s leading players
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.
This industry report offers market estimates of the China market, followed by a detailed analysis of the region. The China market data on pulmonary arterial hypertension can be segmented by region: Central South China, East China, North China, Northeast China, Northwest China, Southwest China.
The report also includes the profiles of leading companies such as Actelion Pharmaceuticals Ltd., Bayer AG, Beijing Tide Pharmaceutical Co. Ltd., GlaxoSmithKline plc, United Therapeutics Corporation.
The data-centric report focuses on market trends, status and outlook for segments. With comprehensive market assessment across the major geographies, the report is a valuable asset for the existing players, new entrants and the future investors.
Why buy this report?
Get a detailed picture of the China Pulmonary Arterial Hypertension Market
Identify segments/areas to invest in over the forecast period in the China Pulmonary Arterial Hypertension Market
Understand the competitive environment, the market’s leading players
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.
Part 1. Summary
Part 2. Introduction
Study period
Geographical scope
Market segmentation
Part 3. Pulmonary arterial hypertension market overview
Part 4. Market breakdown by region
Central South China
East China
North China
Northeast China
Northwest China
Southwest China
Part 5. Key companies
Actelion Pharmaceuticals Ltd.
Bayer AG
Beijing Tide Pharmaceutical Co., Ltd.
GlaxoSmithKline plc
United Therapeutics Corporation
Part 6. Methodology
Part 2. Introduction
Study period
Geographical scope
Market segmentation
Part 3. Pulmonary arterial hypertension market overview
Part 4. Market breakdown by region
Central South China
East China
North China
Northeast China
Northwest China
Southwest China
Part 5. Key companies
Actelion Pharmaceuticals Ltd.
Bayer AG
Beijing Tide Pharmaceutical Co., Ltd.
GlaxoSmithKline plc
United Therapeutics Corporation
Part 6. Methodology
